You just read:

Sorrento Therapeutics And City Of Hope Announce Exclusive License To Develop First-In-Class Immunotherapies Against Intracellular Targets

News provided by

Sorrento Therapeutics, Inc.

Sep 28, 2015, 06:00 ET